-
Oct.292020NEWS
HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating Income, and Net Profit for the Third Quarter
HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating I..
-
Oct.052020NEWS
Chinese Partner HBM Initiated First Dosing of Phase 2 trials of HL161 in MG and ITP in China
Chinese Partner HBM Initiated First Dosing of Phase 2 trials of HL161 in MG and ITP in China
-
Aug.262020NEWS
HL161(batoclimab) Demonstrated Positive Top-line Results in Phase 2 Clinical Trial in Myasthenia Gravis
HL161(batoclimab) Demonstrated Positive Top-line Results in Phase 2 Clinical Trial in Myasthenia Gra..
-
Jul.292020NEWS
HanAll Biopharma recorded KRW 22.6 billion and KRW 1.6 billion in sales and operating income for the second quarter
HanAll Biopharma recorded KRW 22.6 billion and KRW 1.6 billion in sales and operating income for the..
-
Jun.042020NEWS
HanAll Biopharma Appoints Sean Jeong as CEO of HPI, HanAll’s US Subsidiary
HanAll Biopharma Appoints Sean Jeong as CEO of HPI, HanAll’s US Subsidiary
-
Apr.222020NEWS
HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients
HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients